We live in a world of biomedical 'big data' , in which the volume of data is so large and complex that our traditional methods of storage and analysis are challenged. Historically, the most common illustration of this concept has been by reference to nucleotide sequence data. For example, GenBank, the open-access genetic sequence repository of the US National Center for Biotechnology Information (NCBI), has been doubling in size approximately every 18 months since its inception in 1982. The drivers underlying the exponential growth of sequencing data are multiple -continued innovation in computing and digital storage, the declining costs of sequencing and the extension of technology into the microbial and mammalian single-cell levels.
The past 5-10 years have seen biomedical data expand into non-sequence related domains. In the USA, governmental legislation has been an essential force driving the digitization of medical records. By necessity, the subsequent explosion of electronic health record data simultaneously led to the birth of a new field at the intersection of information technology and healthcare known as 'clinical informatics' . In a short time this field has expanded into other platforms, including the patient blogosphere, as well as personalized devices that track sleeping patterns, bowel habits and everything in between. Although much of this data has historically been siloed in the private domain, increasing proportions of it are finally becoming public. This development has been important for many reasons, not least of which is the problem of scientific reproducibility. Indeed, the past several decades have seen an explosion of systematic reviews and meta-analyses adjudicating on conflicting results and proposing field-wide consensuses.
However, we and others are most excited about public data for an entirely different reason: data repurposing. That is, intersecting and slicing datasets along axes orthogonal to those of the original study to unlock novel insights. For example, prior work from our group and others computationally identified a marker for diabetesassociated pancreatic cancer by intersecting published pancreatic cancer gene expression datasets with databases of validated type 2 diabetes mellitus susceptibility genes; the resultant hit (FABP1) was subsequently validated by tissue immuno histochemistry 1 . We used a similar approach of joining public gene expression studies with serum proteomic analysis using protein electrophoresis to identify novel biomarkers for preeclampsia, which were subsequently validated by ELISA 2 . Data repurposing studies performed by our group have also used clinical data, including that from The National Health and Nutrition Examination Survey (NHANES), a programme of the US Centers for Disease Control. Although this annual survey was originally designed to systematically characterize the health and nutritional status of Americans, it has been combined with complementary datasets such as the International Study of Macro/ Micronutrients and Blood Pressure (INTERMAP) to identify micronutrient modulators of blood pressure 3 . NHANES data have also been used as the basis of the first environment-wide association study (EWAS) to identify new chemical mediators of diabetic risk 4 . These examples imply that data repurposing can be most effective when applied across multiple dense and complementary datasets, as might be available for any well-studied complex disease. For this reason, we see this approach as being promising for the future of IBD research. IBD is a complex disease entity with a pathological footprint seen at virtually every level of characterization: genome, transcriptome, microbiome, metabolome, immunome and exposome. Our survey of the public domain confirms that the size and richness of the available data on IBD is tremendous ( Table 1; full  version in Supplementary Table 1) , and this public data will continue to expand.
Despite the complexity and heterogeneity of the disease, we know that IBD is susceptible to the methods of data repurposing because we and others have seen it work before. For example, one study performed a re-analysis of NHANES data and identified the compound 4-tert-octylphenol as a possible environmental toxin associated with ulcerative colitis 6 . This analysis identified differences in plasma cell and inflammatory macrophage counts, which were subsequently validated by immunohistochemistry of tissue biopsy samples from patients with IBD. Their approach also identified a single gene expression signature in peripheral blood (TREM1) that identifies primary non-responders with an area under the receiver-operator curve of 94% 6 . Lastly, our group used public gene expression data to compare disease signatures for IBD against those measured by drug screening. This work identified the anti-epileptic agent topiramate, which was subsequently shown to reverse an animal model of chemically induced colitis 7 . Data repurposing has shown early promise for the study of IBD aetiology, prognosis, and treatment, but we believe that the best is yet to come. For example, not only does the vast majority of structured data go unanalysed, but public data continues to grow rapidly and at a rate outpacing the influx of data scientists. Our survey, summarized in Supplementary Table 1 . reveals new categories of public IBD data that did not exist even 5 years ago, such as the immunome 8, 9 and exposome. Wearables, apps, and the 'Internet of Things' promise to expand these categories of available data further. There is enormous room for newcomers to enter the field and to have an impact.
In addition, our informatics toolkit has never been richer. Breakthroughs in machine learning are starting to enable personalized medicine in ways never before imagined. Natural language processing is also becoming increasingly sophisticated and promises to help unlock the 'dark matter' of unstructured data such as notes and reports. One notable barrier to these approaches in general is privacy concerns. Nevertheless, some groups have already succeeded in de-identifying their notes for public consumption 10 , and more are sure to follow.
We are optimistic that these tools will continue to grow in potential, releasing increasing quantities of valuable clinical content into the open domain. Finally, the most compelling rationale for our advocacy of data repurposing is that it can be done by anyone with little more than a computer and Internet access. Of course, all computationally-identified targets require experimental validation to be trustworthy. But short of this process, and especially for an increasingly global disease, data repurposing is a method that can scientifically engage everyone, everywhere. 
